SMO and basal cell carcinoma: Apart from cyclopamine, another synthetic small molecule inhibitors of Smo, GDC-0449 identified by Genentech was shown to inhibit the Hh pathway activity in metastatic basal cell carcinoma (ClinicalTrials.govnumber, NCT00607724).101 Oral administration of GDC-0449 was given to 33 patients with advanced basal cell carcinoma for a median duration of 9.8 months and reported two complete responses and 16 partial responses.101 GDC-0449 was also shown to have its inhibitory effect in medulloblastoma, pancreatic cancer but its effect is more prominent in advanced basal cell carcinoma.